Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleximenib phase 1/2 study in acute leukemia
NL-OMON60221Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bleximenib in Acute Leukaemia and acute myeloid leukemia (AML) (3 arms), sponsored by Janssen Pharmaceutical. Planned start May 2021; status: withdrawn.
02
Drugs
bleximenib
03
Conditions
Acute Leukaemiaacute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON60221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60221.